Product Images Donepezil Hydrochloride

The text describes a chart or graph that shows the percentage of patients who have taken either Donepezil Hydrochloride 10mg/day or 5mg/day or a placebo. Below the chart, there is a rating system called CIBIC-plus, which rates the improvement of the patients from markedly improved to minimally improved or worse.*

This appears to be a chart / graph of a clinical study evaluating the effect of Donepezil Hydrochloride on clinical improvement and decline over several weeks of drug treatment compared to placebo. There are two different dosage options given (10mg/day and 5mg/day) and the chart shows that patients on Donepezil Hydrochloride experienced a higher level of clinical improvement compared to placebo, as well as a slower rate of decline.*

This appears to be a clinical research data table showing the change in ADAS-cog for different treatments groups. The treatments include Donepezil, Hydrochloride 10 mg/day, Hydrochloride 5 mg/day, and a placebo. The table also includes the cumulative percentage of patients for each treatment group.*

This appears to be a table showing the percentage of patients categorized by the degree of improvement with different dosages of Donepezil Hydrochloride and Placebo. The table also includes a rating scale called CIBIC-plus Rating to measure the change in the patient's condition.*

The text seems to be a table showing the mean change from baseline for SIB (Severe Impairment Battery) score after 3 to 6 months of drug treatment in a clinical trial. The first column indicates the treatment group (Donepezil Hydrochloride 10 mg/day or Placebo), while the second column shows the mean change in SIB score. The third row mentions "Clinical Decline".*

This appears to be a chart or table pertaining to a clinical trial. It shows the administration of either Donepezil Hydrochloride or a placebo at a dosage of 10 mg/day, with measurements taken at 5, 30, and 45 time intervals. The text includes a data point called "SIB Change from Baseline".*

The text describes a medication called Donepezil Hydrochloride that is taken at a dosage of 10 milligrams per day. There is a comparison to a placebo indicated on a chart with varying percentages. The text references an "ADCS-ADL Change from Baseline" score, but no further information is provided to clarify the meaning of the score.*

The given text seems to be a chart or graph that shows the effects of Donepezil Hydrochloride at different dosages on clinical improvement and decline. It is not possible to provide further details or interpretation without additional context or information.*

This text appears to be a medication prescription for Donepezil Hydrochloride with two different doses mentioned: 23 mg/day and 10 mg/day. The remaining text seems to be a chart indicating the status of the medication's effect on the patient, ranging from improvement to worsening. Therefore, it may be a medical document related to the dosage and performance of Donepezil Hydrochloride.*

This is a description of Donepezil HCI 10mg tablets with NDC 63187-401-30. The tablets are white to off-white, round, film-coated and are debossed with “J” on one side and “10" on the other side. The product ID is RD040130, and they are manufactured by Jubilant Life Sciences Limited in Roorkee-247661, India. The tablets are available in a pack of 30 with lot #: 00000 Exp: 00/00/00. The medication should be stored at 20°-25°C (68°-77°F) and out of the reach of children. The product has been relabeled by Proficient Rx LP located in Thousand Oaks, CA 91320.*